| Name | Title | Contact Details |
|---|
Heart Force Medical Inc. (HFM), a private company, has invented and has patents pending for the digital Ballistocardiograph (dBG(TM)). The dBG 300, which is already approved in Canada and the United States, captures the movement of the heart during each cardiac cycle (heart beat). This movement (acceleration and force) is sensed by an accelerometer aligned to the three principal axes and displayed on a computer screen using HFM's proprietary software. Preliminary evaluation has determined that a 10-30 second recording of the dBG waveform is sufficient for a detailed analysis of cardiac performance. The Heart Force dBG 300 device is a non-invasive, standalone, portable unit and contains sophisticated digital sensors and proprietary software.
SunLink Health Systems, Inc. currently operates seven community hospitals and related nursing home and home care businesses in the Southeast and Midwest, and its specialty pharmacy business, SunLink Scripts Rx, in Louisiana and Georgia. Each SunLink hospital is the only hospital in its community. SunLink's operating strategy is to link patients' needs with dedicated physicians and health professionals to deliver quality, efficient medical care and healthcare products and services in each area it serves. For additional information on SunLink Health Systems, Inc.
Trinity Health is a nonprofit, integrated care system serving northwest/central North Dakota and Eastern Montana. With a tertiary care hospital in Minot, close to a dozen rural health clinics, and a long-term care facility, Trinity provides a full complement of healthcare services to the region.
Cgmp Validations is a Mission, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AstraZeneca is a global, science-led biopharmaceutical company that spans the discovery, development, manufacturing, distribution and worldwide commercialisation of primary care and speciality care medicines. We believe the best way we can help patients is to focus on breakthrough science in order to uncover disease mechanisms and develop novel, targeted therapies that interact with them. This is at the heart of our purpose as a company: to push the boundaries of science to deliver life-changing medicines. We invest in distinctive science in three main therapy areas where we believe we can make the most meaningful difference to patients: oncology; cardiovascular and metabolic diseases; and respiratory, inflammation and autoimmunity. Our science exploits our rare combination of capabilities in small molecules and biologics, immunotherapies, protein engineering technologies and devices. These are reinforced by a strong focus on translational science and personalised healthcare capabilities. We build on our own capabilities by collaborating with world-renowned scientists and academic institutions and partnering with like-minded science-led companies. Through leading in science, we are confident that we can transform the lives of people around the world and deliver value to our shareholders.